

Gilead and Kite Research Scholars Program in Hematologic Malignancies

Now accepting applications!

\$130,000 USD for two years, to be paid in annual installments of up to \$65,000 USD per year.*

Gilead's Research Scholars Program supports innovative research from emerging investigators around the world to advance scientific knowledge in areas of unmet medical needs and to improve the lives of patients everywhere.

The program is designed to support innovative translational research projects in hematological malignancies that can be based around either a clinical trial or laboratory investigation.

Gilead's Research Scholars Program is committed to building a more diverse and inclusive scientific community.

Eligibility Criteria

Applications will be reviewed and selected by an independent Scientific Review Committee composed of internationally recognized experts in translational research in the field of hematology/oncology.

To be eligible, applicants must:

- Hold an MD or PhD (or equivalent degree) at the time of award
- Early to Mid-career scientists with a strong research track record who hold a position at a recognized research institution in one of the eligible countries at the time of application and whose tenure of that position encompasses the projected period of the award
- This program is designed for non-faculty members who are within 3-5 years of obtaining a faculty appointment. MD or PhD qualifications would have to have been obtained within the last 8 years.
 Exceptions can apply.
- Have a strong career interest in hematology/ oncology
- Have a research mentor with extensive experience in the field of hematology/oncology
- Be able to devote approximately 50% of their professional time to research for the next two years
- Be able to complete the proposed research within the two-year award period.

Visit: https://researchscholars.gilead.com/en/ intl_hematologic_malignancies_portal for complete program and eligibility information and to submit an application.

Deadline to apply:

21 March 2022









*Awards are subject to separate terms and conditions.